Vaccine

• Biotech companies including Soligenix, Moderna, Regeneron, and Aethlon Medical are accelerating the development of vaccines and therapeutics to combat a global outbreak of Bundibugyo ebolavirus in 2026. • Regeneron's maftivimab, a potent antibody found in the FDA-approved Inmazeb, has been recommended by the WHO's Therapeutics Advisory Group for use in clinical trials. • Aethlon Medical (Nasdaq:AEMD) is preparing to coordinate with global health authorities to deploy its Hemopurifier device as part of the medical response.

• JAMA Network Open has published a taxpayer-funded study on COVID-19 vaccines that federal officials at the CDC previously declined to release. • The study examines vaccine efficacy and safety, raising questions about why the CDC initially squelched the data and whether the decision was based on political motivations or a desire to protect public confidence. • This controversy highlights ongoing tensions regarding government transparency and the potential suppression of scientific data during the pandemic response.

• A study confirming the effectiveness of COVID-19 vaccines was published Tuesday by JAMA Network Open after being blocked by a CDC journal. • The research found the vaccine was approximately 55% effective against hospitalizations and reduced emergency department and urgent care visits by 50%. • The publication gained significant attention because political appointees from the Trump administration previously prevented the findings from appearing in a government health publication.

• The CDC canceled the publication of a COVID-19 vaccine effectiveness study originally scheduled for its flagship Morbidity and Mortality Weekly Report (MMWR) in April. • CDC leadership blocked the report citing "methodologic weaknesses," though the study has since been released for public review. • Dr. F. Perry Wilson of the Yale School of Medicine highlighted the incident, raising questions about transparency and the potential suppression of data by health officials.

Reports say Texas recruits ill from outbreak, which comes weeks after defense secretary made flu vaccine optionalAn influenza outbreak has reportedly sickened more than 150 recruits in training at Lackland air force base in San Antonio, Texas.The outbreak comes just weeks after the defense secretary, Pete Hegseth, ended mandatory flu vaccination for the military, citing the need for bodily autonomy for servicemembers. Continue reading...

• The U.S. FDA has approved Merck's pneumococcal vaccine for expanded use in children and teenagers with chronic health conditions that increase their risk of infection. • This follows a June 2024 approval for adults and is based on a late-stage trial of 874 participants where the vaccine matched or outperformed the older PPSV23 version. • The approval is critical because pneumococcal disease can cause life-threatening conditions, including meningitis, pneumonia, and blood infections, particularly in high-risk youth.

Moderna seeks FDA approval of its new shot, mFlusvia, as option for 50 and olderUS health advisers are debating a new kind of flu vaccine Thursday, the first made with the same mRNA technology that was key to ending the Covid-19 pandemic.Moderna is seeking Food and Drug Administration (FDA) approval of its new shot , dubbed mFlusiva, as an option for people 50 and older. The FDA advisory committee meeting is a step toward a final decision ahead of the winter flu season. Continue reading...